# CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

> **NCT03292809** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novaliq GmbH** · enrollment: 328 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** CyclASol topical ocular, eye drops
- **DRUG:** Vehicle topical ocular, eye drops

## Key facts

- **NCT ID:** NCT03292809
- **Lead sponsor:** Novaliq GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-06-20
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292809, "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03292809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*